BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044343
CREATED:20250620T105534Z
LAST-MODIFIED:20250620T105629Z
UID:41341-1761004800-1761263999@www.pharmajournalist.com
SUMMARY:7th Gene Therapy Analytical Development Summit
DESCRIPTION:Driving Analytical Excellence from Pre-IND Through BLA for Next-Generation Gene Therapies \nReturning to Boston this October\, the 7th Gene Therapy Analytical Development Summit is the industry’s definitive meeting for advancing assay development and analytical strategy across the gene therapy lifecycle. As gene therapy platforms expand beyond AAV to encompass mRNA\, CRISPR-based modalities\, LNPs\, and novel capsids\, analytical teams must evolve in parallel to meet growing regulatory scrutiny and technical complexity. \nThis summit brings together analytical development\, QC\, and regulatory experts to share practical insights on validating potency assays\, genome integrity\, and advanced characterization tools to ensure product consistency\, safety\, and regulatory readiness from early development through to BLA and commercial launch. \nWith expert contributions from leaders at Beam Therapeutics\, Sarepta\, Astellas\, Spark Therapeutics\, Adverum\, REGENXBIO\, and GenSight Biologics\, attendees will explore real-world solutions to persistent challenges in full or empty capsid quantification\, aggregation profiling\, stability assay design\, and assay transfer into GMP environments. \nFeatured speakers include Johnson Varghese\, Vice President of Analytical Sciences at Beam Therapeutics\, sharing phase-appropriate validation strategies\, and Sue Duan\, Head of Analytical Development at Astellas\, who will discuss genome integrity testing across multiple vector platforms. Also presenting are Uditha DeAlwis of Sarepta Therapeutics and Vanessa Strings-Ufombah from Adverum Biotechnologies\, offering unique perspectives on aligning assay strategies with global regulatory expectations. \nAttendees will gain exposure to cutting-edge techniques including long-read sequencing\, digital PCR\, analytical ultracentrifugation\, and mass photometry\, with a focus on integrating these tools into QC-ready workflows that meet IND\, BLA\, and RMAT requirements. \nWith two technical tracks\, this event delivers unmatched depth across bioassays\, molecular analytics\, and physicochemical characterization\, empowering you to optimize existing platforms or develop robust analytics for new therapeutic modalities. \nWhether refining potency assays\, reducing batch variability\, or preparing for regulatory submission\, this is your opportunity to benchmark with peers and shape the future of gene therapy analytics in 2025 and beyond. \nDownload the Brochure Here for More Information: https://ter.li/wld1o2
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251022
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044343
CREATED:20250731T101641Z
LAST-MODIFIED:20250731T101641Z
UID:41595-1761091200-1761263999@www.pharmajournalist.com
SUMMARY:3rd Spatial Biology for Drug Development Summit
DESCRIPTION:The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on. \n \nAcross an intensive 2-day agenda\, you’ll explore practical solutions to issues spanning data infrastructure\, multi-omics integration\, standardization\, scalability\, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights\, robust target identification\, biomarker discovery\, and more. \nFind out more here: https://ter.li/otrpyk \nSpatial biology is at a turning point. Rapid advances in resolution\, sensitivity\, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments\, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin\, highlight the strong momentum and confidence building across the sector. Yet\, challenges around data standardization\, integration\, scalability\, and cost continue to limit widespread adoption\, particularly among small and mid-sized biopharma companies. \nNo other meeting will give you the chance to connect with 70+ spatial biology experts for *free and take away fresh\, actionable data from AstraZeneca\, Takeda\, AbbVie\, Genentech\, Amgen\, Pfizer\, Johnson & Johnson\, and many more – the exact people you need to meet to move your work forward. \nJoin the spatial biology community (for free) here: https://ter.li/fvnrcc
URL:http://www.pharmajournalist.com/event/3rd-spatial-biology-for-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR